The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide.
Stein
P D
PD
Department of Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000.
Hunt
J T
JT
Floyd
D M
DM
Moreland
S
S
Dickinson
K E
KE
Mitchell
C
C
Liu
E C
EC
Webb
M L
ML
Murugesan
N
N
Dickey
J
J
D000818:Animals; D000959:Antihypertensive Agents / Q000138:chemical synthesis / Q000627:therapeutic use; D002460:Cell Line; D003619:Dansyl Compounds / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000378:metabolism; D006973:Hypertension / Q000188:drug therapy; D015394:Molecular Structure; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D013329:Structure-Activity Relationship
D000959:Antihypertensive Agents; D003619:Dansyl Compounds; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; C085754:5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide